Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Synageva BioPharma has expanded its collaboration with Mitsubishi Tanabe Pharma (MTPC) to develop a second protein therapeutic for an undisclosed orphan disease.
Subscribe to our email newsletter
The collaboration will leverage Synageva’s product development capabilities and proprietary protein expression platform.
As per the agreement, Mitsubishi will make an upfront payment of $9m and Synageva will receive reimbursement for development costs, potential future development and commercial milestone payments, as well as royalties from potential product revenue.
MTPC global product strategy executive officer, board director Masayuki Mitsuka said: "The synergy of Synageva’s innovative technologies and MTPC’s expertise in R&D of biologics will seek to create protein therapeutics that contribute to healthy life around the world."